Fed Governor Williams spoke this morning and struck a calm tone. He said monetary policy is "well positioned" and risks are balanced. He flagged that inflation remains elevated but energy price declines should help. Markets read this as no imminent rate cut. Traders are pricing steady policy through the summer.
The biggest options signal today is in pharma. EXEL put-call ratio hit 1.33 — 4.1 standard deviations above its 20-day average. Short interest already sits near 15% of free float. Bears are pressing hard from multiple angles. Separately, RVMD got a boost as the European Medicines Agency began a phased review of its pancreatic cancer drug daraxonrasib. VRTX also drew attention after flagging over $5 billion in peak sales potential from its Crinetics acquisition. Analysts lifted MRNA's target to $47.37 — short interest there sits at 16.5% of free float, a potential squeeze setup if sentiment turns further.
NVDA faces a fresh challenge. Reports say DeepSeek is building its own AI chip. That hit the $4.7 trillion giant mid-session. Meanwhile, investor Ross Gerber publicly dismissed Michael Burry's short position in MU, calling it "a joke" and citing AI-driven demand as a structural tailwind.
Analyst targets swept higher across financials today. JPM and WFC both received upgrades after strong Q2 results. The big bank reporting season kicks into full gear on July 14, when Wells Fargo, C, and BAC all report on the same day. SHEL rose in European trade, adding to the energy sector's steadier tone as oil prices hold support.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
